BRPI1013559A2 - compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos - Google Patents

compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos

Info

Publication number
BRPI1013559A2
BRPI1013559A2 BRPI1013559A BRPI1013559A BRPI1013559A2 BR PI1013559 A2 BRPI1013559 A2 BR PI1013559A2 BR PI1013559 A BRPI1013559 A BR PI1013559A BR PI1013559 A BRPI1013559 A BR PI1013559A BR PI1013559 A2 BRPI1013559 A2 BR PI1013559A2
Authority
BR
Brazil
Prior art keywords
compounds
pharmaceutical composition
condition associated
treating disease
trpa1 function
Prior art date
Application number
BRPI1013559A
Other languages
English (en)
Portuguese (pt)
Inventor
Abraham Thomas
Ashok Bhausaheb Kadam
Indranil Mukhopadhyay
Neelima Khairatkar-Joshi
Nisha Parag Patil
Rajendra Prakash Chikhale
Sachin Sundarlal Chaudhari
Sachin Vasantrao Dhone
Sukeerthi Kumar
Vishal Govindrao Deshmukh
Original Assignee
Glenmark Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glenmark Pharmaceuticals Sa filed Critical Glenmark Pharmaceuticals Sa
Publication of BRPI1013559A2 publication Critical patent/BRPI1013559A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI1013559A 2009-03-23 2010-03-17 compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos BRPI1013559A2 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
IN665MU2009 2009-03-23
US17135509P 2009-04-21 2009-04-21
IN2212MU2009 2009-09-23
IN2211MU2009 2009-09-23
US25194409P 2009-10-15 2009-10-15
US25326309P 2009-10-20 2009-10-20
IN2891MU2009 2009-12-15
IN2892MU2009 2009-12-15
US29446310P 2010-01-12 2010-01-12
US30024110P 2010-02-01 2010-02-01
PCT/IB2010/000553 WO2010109287A1 (en) 2009-03-23 2010-03-17 Fused pyrimidine-dione derivatives as trpa1 modulators

Publications (1)

Publication Number Publication Date
BRPI1013559A2 true BRPI1013559A2 (pt) 2016-04-12

Family

ID=42780198

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1013559A BRPI1013559A2 (pt) 2009-03-23 2010-03-17 compostos, composição farmacêutica, método de tratamento de doença ou condição associada à função trpa1 e respectivos usos

Country Status (23)

Country Link
US (1) US9000159B2 (enExample)
EP (2) EP2411393B1 (enExample)
JP (1) JP5657638B2 (enExample)
KR (1) KR20110132575A (enExample)
CN (1) CN102361873B (enExample)
AP (1) AP3280A (enExample)
AU (1) AU2010227245B2 (enExample)
BR (1) BRPI1013559A2 (enExample)
CA (1) CA2756518A1 (enExample)
CL (2) CL2011002315A1 (enExample)
DK (1) DK2411393T3 (enExample)
EA (1) EA023857B1 (enExample)
ES (2) ES2456515T3 (enExample)
IL (1) IL215178A (enExample)
MX (1) MX2011009824A (enExample)
PE (1) PE20120774A1 (enExample)
PL (1) PL2411393T3 (enExample)
PT (1) PT2411393E (enExample)
SG (1) SG174402A1 (enExample)
SI (1) SI2411393T1 (enExample)
UA (1) UA108069C2 (enExample)
WO (1) WO2010109287A1 (enExample)
ZA (1) ZA201107648B (enExample)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008019357A2 (en) 2006-08-07 2008-02-14 Ironwood Pharmaceuticals, Inc. Indole compounds
ES2456515T3 (es) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
KR101591153B1 (ko) 2010-12-20 2016-02-02 그렌마크 파머수티칼스 에스. 아. Trpa1 길항제로서의 2-아미노-4-아릴티아졸 화합물
AR084433A1 (es) 2010-12-22 2013-05-15 Ironwood Pharmaceuticals Inc Inhibidores de la faah y composiciones farmaceuticas que los contienen
EP2520566A1 (en) 2011-05-06 2012-11-07 Orion Corporation New Pharmaceutical Compounds
RU2014100744A (ru) 2011-06-13 2015-07-20 Гленмарк Фармасьютикалс С.А. Лечение респираторных нарушений с помощью trpa1 антагонистов
WO2012176105A1 (en) 2011-06-22 2012-12-27 Glenmark Pharmaceuticals Sa Pharmaceutical composition comprising a trpa1 antagonist and a leukotriene receptor antagonist
JP2014517062A (ja) 2011-06-22 2014-07-17 グレンマーク ファーマシューティカルズ， エセ．アー． ＴＲＰＡ１アンタゴニスト及びβ２アゴニストを含む医薬組成物
US20140148423A1 (en) 2011-07-25 2014-05-29 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and a steroid
KR20140073496A (ko) 2011-08-09 2014-06-16 하이드라 바이오사이언시스, 인코포레이티드 일과성 수용체 잠재 이온채널 trpa1의 억제
US20140364445A1 (en) 2011-12-05 2014-12-11 Glenmark Pharmaceuticals S.A. Pharmaceutical composition comprising a trpa1 antagonist and an anticholinergic agent
EP2805718B1 (en) 2012-01-17 2018-04-04 EA Pharma Co., Ltd. Heterocyclic amide derivative and pharmaceutical product containing same
AU2013273118B2 (en) 2012-06-08 2015-11-05 Glenmark Pharmaceuticals S.A. Amides of 2-amino-4-arylthiazole compounds and their salts
PE20150598A1 (es) 2012-10-01 2015-05-20 Orion Corp Derivados de n-prop-2-inil carboxamida y su uso como antagonistas del receptor transitorio potencial de la subfamilia a, miembro 1
US9394308B2 (en) 2013-01-18 2016-07-19 Merck Sharp & Dohme Corp. Inhibiting the transient receptor potential A1 ion channel
MX2016004741A (es) 2013-10-15 2016-07-26 Glenmark Pharmaceuticals Sa Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
RU2674977C2 (ru) 2013-10-30 2018-12-14 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Производные пиразолопиримидона или пирролотриазона, способ их получения и их фармацевтические применения
CN103755705B (zh) * 2014-02-17 2017-02-15 上海佰特因医药科技有限公司 一种天然产物四甲基尿酸的全合成方法
JP6667092B2 (ja) * 2014-08-11 2020-03-18 ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーＨｙｄｒａ Ｂｉｏｓｃｉｅｎｃｅｓ， ＬＬＣ ピロロ［３，２−ｄ］ピリミジン−２，４（３Ｈ，５Ｈ）−ジオン誘導体
WO2016042501A1 (en) 2014-09-16 2016-03-24 Glenmark Pharmaceuticals S.A. Trpa1 antagonist for the treatment of pain associated to diabetic neuropathic pain
CN105001170A (zh) * 2015-07-13 2015-10-28 佛山市赛维斯医药科技有限公司 末端腈基取代的三氮唑亚砜类化合物、其制备方法及其用途
WO2017060488A1 (en) 2015-10-09 2017-04-13 Almirall, S.A. New trpa1 antagonists
WO2017064068A1 (en) 2015-10-14 2017-04-20 Almirall, S.A. New trpa1 antagonists
AU2018305633B2 (en) * 2017-07-28 2022-11-24 Jiangsu Hengrui Medicine Co., Ltd. Method for preparing pyrimidone heteroaryl derivative and intermediate of pyrimidone heteroaryl derivative
CN109422749B (zh) * 2017-08-21 2023-01-24 重庆医药工业研究院有限责任公司 一种抑制单羧酸转运蛋白的嘧啶二酮衍生物
US10710994B2 (en) 2018-03-19 2020-07-14 Genentech, Inc. Oxadiazole transient receptor potential channel inhibitors
CN108558836A (zh) * 2018-05-14 2018-09-21 东南大学 一类具有双重作用机制的dpp-4抑制剂及其用途
WO2023096915A1 (en) * 2021-11-24 2023-06-01 Slap Pharmaceuticals Llc Multicyclic compounds
US20250136587A1 (en) * 2022-02-03 2025-05-01 D. E. Shaw Research, Llc N3-substituted uracil compounds as trpa1 inhibitors
US20250214980A1 (en) 2022-03-14 2025-07-03 Slap Pharmaceuticals Llc Multicyclic compounds
CN114656472B (zh) * 2022-04-27 2023-07-04 成都施贝康生物医药科技有限公司 吡唑并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656473B (zh) * 2022-04-27 2023-09-29 成都施贝康生物医药科技有限公司 吡咯并嘧啶类化合物、异构体或盐及其制备方法和用途
CN114656480B (zh) * 2022-04-27 2024-01-26 成都施贝康生物医药科技有限公司 噻吩并嘧啶类化合物、异构体或盐及其制备方法和用途
CN118373832B (zh) * 2023-01-20 2025-01-28 深圳晶蛋生物医药科技有限公司 大环类化合物、其药物组合物及其应用
WO2025264860A2 (en) 2024-06-18 2025-12-26 Yale University Methods of treating post-covid airway disease

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2248231A1 (de) 1972-10-02 1974-04-11 Basf Ag 3-aminoisothiazolo eckige klammer auf 3,4-d eckige klammer zu pyrimidine
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
ES2193839B1 (es) 2001-06-22 2005-02-16 Almirall Prodesfarma, S.A. Nuevos derivados de 6-fenildihidropirrolpirimidindiona.
AU2003253165A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc Pyrimidine fused bicyclic metalloproteinase inhibitors
WO2004055054A1 (en) 2002-12-18 2004-07-01 Novartis Ag Anktm1, a cold-activated trp-like channel expressed in nociceptive neurons
EP1713815A4 (en) 2004-02-11 2009-03-11 Smithkline Beecham Corp PTH AGONISTS
WO2005089206A2 (en) 2004-03-13 2005-09-29 Irm Llc Modulators of ion channel trpa1
MY140748A (en) 2004-12-06 2010-01-15 Astrazeneca Ab Novel pyrrolo [3,2-d] pyrimidin-4-one derivatives and their use in therapy
JPWO2006083005A1 (ja) 2005-02-03 2008-06-26 武田薬品工業株式会社 縮合ピリミジン誘導体およびその用途
US20060291462A1 (en) * 2005-06-28 2006-12-28 Utstarcom, Inc. Method and apparatus using multiple application cards to comprise multiple logical network entities
EP1962855B1 (en) * 2005-12-22 2013-08-21 Hydra Biosciences, Inc. Trpa1 inhibitors for treating pain
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
WO2008094909A2 (en) 2007-01-29 2008-08-07 Xenon Pharmaceuticals Inc. Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2009002933A1 (en) * 2007-06-22 2008-12-31 Hydra Biosciences, Inc. Methods and compositions for treating disorders
WO2009158719A2 (en) 2008-06-27 2009-12-30 Hydra Biosciences, Inc. Methods and compositions for treating disorders
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
BRPI1009372A2 (pt) 2009-03-23 2016-05-31 Glenmark Pharmaceuticals Sa compostos, composição farmacêutica e respectivos usos
ES2456515T3 (es) 2009-03-23 2014-04-22 Glenmark Pharmaceuticals S.A. Derivados de pirimidindiona fusionados como moduladores de TRPA1
PE20120834A1 (es) 2009-03-23 2012-07-25 Glenmark Pharmaceuticals Sa Derivados de furopirimidindiona como moduladores de trpa1
AR076332A1 (es) 2009-04-21 2011-06-01 Boehringer Ingelheim Int Derivados heterociclicos de 5-alquinil-piridinas, composiciones farmaceuticas que los comprenden y uso de los mismos para el tratamiento y/o prevencion del cancer, procesos inflamatorios, autoinmunes, y/o infecciones.
CN102802416A (zh) 2009-06-18 2012-11-28 巴斯夫欧洲公司 杀真菌混合物
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
AU2010308028A1 (en) 2009-10-15 2012-04-19 Pfizer Inc. Pyrrolo[2,3-d] pyrimidine compounds
AR078522A1 (es) 2009-10-15 2011-11-16 Lilly Co Eli Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
EP2311844A1 (en) 2009-10-15 2011-04-20 Interquim, S.A. Silyl polymeric benzoic acid ester compounds, uses, and compositions thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
CN102666507B (zh) 2010-07-13 2014-09-17 诺华股份有限公司 噁嗪衍生物及其在治疗神经病症中的用途

Also Published As

Publication number Publication date
EP2708538A1 (en) 2014-03-19
JP2012521401A (ja) 2012-09-13
EA201190143A1 (ru) 2012-04-30
WO2010109287A1 (en) 2010-09-30
PL2411393T3 (pl) 2014-06-30
AU2010227245A1 (en) 2011-09-22
ZA201107648B (en) 2012-07-25
CA2756518A1 (en) 2010-09-30
KR20110132575A (ko) 2011-12-08
US20140128603A1 (en) 2014-05-08
CN102361873B (zh) 2014-07-09
SG174402A1 (en) 2011-10-28
IL215178A (en) 2015-01-29
ES2456515T3 (es) 2014-04-22
UA108069C2 (uk) 2015-03-25
CL2011002315A1 (es) 2012-04-09
EP2411393A4 (en) 2012-08-01
DK2411393T3 (da) 2014-04-07
EA023857B1 (ru) 2016-07-29
AP3280A (en) 2015-05-31
JP5657638B2 (ja) 2015-01-21
SI2411393T1 (sl) 2014-03-31
MX2011009824A (es) 2012-01-25
PT2411393E (pt) 2014-02-21
ES2551085T3 (es) 2015-11-16
AU2010227245B2 (en) 2015-09-10
AP2011005887A0 (en) 2011-10-31
PE20120774A1 (es) 2012-06-27
IL215178A0 (en) 2011-12-29
HK1194742A1 (en) 2014-10-24
US9000159B2 (en) 2015-04-07
EP2411393A1 (en) 2012-02-01
CN102361873A (zh) 2012-02-22
HK1166075A1 (en) 2012-10-19
EP2708538B1 (en) 2015-08-12
AU2010227245A2 (en) 2011-10-27
CL2014001447A1 (es) 2014-10-17
EP2411393B1 (en) 2014-01-22

Similar Documents

Publication Publication Date Title
BRPI1013705A2 (pt) compostos, composição farmacêutica, método de tratamento de doença ou condição associada com função de trap1 e usos de compostos e de composição farmacêutica
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
BR112013013435A2 (pt) composto, composição farmacêutica, uso de um composto, método para a profilaxia ou tratamento de um estado ou condição de doença mediados por uma cinase de fgfr, e, processo para a preparação de um composto.
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BR112014021103A8 (pt) anticorpo, composição farmacêutica, droga de combinação, dna, método de tratamento e uso de anticorpo
BR112013011968A2 (pt) composição farmacêutica, métodos de tratamento e usos da mesma
BRPI1013984A2 (pt) composto , composição farmacêutica, método para tratamento ou profilaxia de uma doença ou condição, e, uso de um composto.
BR112012003464A2 (pt) composto, composição farmacêutica, usos de uma composição farmacêutica e de um composto, e, método para tratar uma doença ou um distúrbio."
BRPI1013640A2 (pt) composicao farmaceutica, metodos para o tratamento e usos dos mesmos
BRPI0920026A2 (pt) método de tratamento de infecção pulmonar, composição farmacêutica e respectivos usos.
BR112014002621A2 (pt) anticorpo, composição farmacêutica, combinação farmacêutica, dna e método de tratamento
BRPI0909179A2 (pt) Composição farmacêutica, e, método de tratamento de uma doença autoimune.
BR112014004181A2 (pt) composto, composição farmacêutica, e, método de tratamento, prevenção, e / ou retardo do início de uma doença ou patologia
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
HUE049880T2 (hu) Anyag és eljárások Her-3-mal összefüggõ betegségek kezelésére vagy megelõzésére
BR112012018947A8 (pt) composição farmacêutica para o tratamento e/ou prevenção de um câncer, anticorpo, combinação farmacêutica e método para o tratamento e/ou prevenção de um câncer
BRPI1013396A2 (pt) composto, produto farmacêutico de combinação, uso de um composto, método para tratar uma doença ou condição, e, processo para a preparação de um composto.
BR112012018951A2 (pt) composição farmacêutica, combinação farmacêutica e método para o tratamento e\ou prevenção de um câncer e anticorpo
BR112012004333A2 (pt) composto, composição farmacêutica, e, método para o tratamento ou a prevenção de uma doença ou um distúrbio.
BRPI0909180A2 (pt) composição farmacêutica, e, método de tratamento de uma doença autoimune
PT2729151T (pt) Composição farmacêutica, métodos de tratamento e suas utilizações
BRPI0909048A2 (pt) composição farmacêutica, e, método de tratamento de uma doença autoimune
BRPI0915267A2 (pt) Composto, composição farmacêutica livre de pirogênio, e, método de tratamento de uma doença ou uma condição
BR112014032510A2 (pt) composto, composição farmacêutica, método para tratar ou prevenir uma doença ou desordem, e, uso de um composto.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]